MarginsXMarginsX
Home › Markets › Health Care › BOLD

Boundless Bio Inc. (BOLD)

BOLD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.41
-3.60% on the day
Market cap
$56.9M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerBOLD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0001782303
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
7.4 months
$34.9M cash at September 30, 2026
Share count, 1 year
+5.5%
2025-10-31 to 2026-11-06
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$1.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$34.9M cash; operating cash flow -$14.2M a quarter.Report 2026-09-30
Shares outstanding23,611,406 (2026-11-06); 22,385,611 a year earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Diego, California, United StatesPCAOB Form AP 2026-04-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.5M, sold $94K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$5.4M-$10.9M$34.9MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$23.7M-$21.0M$20.2MNo debt tagsNeeds four quarters10-Q 2026-08-07
Q1 2026
2026-03-31
Not filed-$13.6M-$15.0M$17.5MNo debt tagsNeeds four quarters10-Q 2026-05-08
Q4 2025
2025-12-31
Not filed-$12.9M-$10.1M$17.9MNo debt tagsNeeds four quarters10-K 2026-03-09
Q3 2025
2025-09-30
Not filed-$13.9M-$10.2M$15.0MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$15.7M-$11.8M$14.7MNo debt tagsNeeds four quarters10-Q 2026-08-07
Q1 2025
2025-03-31
Not filed-$15.8M-$14.5M$15.1MNo debt tagsNeeds four quarters10-Q 2026-05-08
Q4 2024
2024-12-31
Not filed-$16.4M-$15.6M$26.6MNo debt tagsNeeds four quarters10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-11-03
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-08-28
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 165 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.6%
1 month+2.9%
3 months-9.9%
Year to date+108.3%
1 year+108.3%
From 52-week high-16.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
XBITXBiotech Inc.$1.85-5.37%$56.4M
FBIOFortress Biotech Inc.$1.71-9.04%$57.7M
TNXPTonix Pharmaceuticals Holding Corp.$2.88-4.32%$56.0M
SPROSpero Therapeutics Inc.$0.9464-5.35%$55.1M
VRCAVerrica Pharmaceuticals Inc.$3.20-10.11%$55.0M
CINGCingulate Inc.$3.75-12.79%$54.5M
INCRIntercure Ltd.$3.63-4.22%$54.5M
AZRAzora Therapeutics Inc.$3.81-6.85%$54.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier